Andriani G. Charpidou

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Dermatologic adverse events associated with amivantamab: A multicentre study.

Dermatologic adverse events associated with amivantamab: A multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2025

AΙ-Driven Drug Repurposing: Applications and Challenges.

AΙ-Driven Drug Repurposing: Applications and Challenges.

Journal: Medicines (Basel, Switzerland)

Published: July 25, 2025

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.

Journal: Cureus

Published: June 30, 2025

Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review.

Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review.

Journal: Oncology research

Published: April 02, 2025

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.

Journal: NPJ precision oncology

Published: March 23, 2025

Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.

Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.

Journal: Future oncology (London, England)

Published: January 09, 2025

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma.

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma.

Journal: Clinical lung cancer

Published: December 27, 2024

Histologic Transformation in Cancer: The Path for Clinical Translation.

Histologic Transformation in Cancer: The Path for Clinical Translation.

Journal: Cancer discovery

Published: December 20, 2024

ERS Congress 2024: highlights from the Thoracic Oncology Assembly.

ERS Congress 2024: highlights from the Thoracic Oncology Assembly.

Journal: ERJ open research

Published: November 08, 2024

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).

Journal: Current oncology (Toronto, Ont.)

Published: July 03, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026